Compare DINO & PODD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | DINO | PODD |
|---|---|---|
| Founded | 1947 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Medical/Dental Instruments |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.9B | 10.3B |
| IPO Year | 2022 | 2007 |
| Metric | DINO | PODD |
|---|---|---|
| Price | $69.73 | $152.33 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 15 | 21 |
| Target Price | $61.50 | ★ $341.48 |
| AVG Volume (30 Days) | ★ 2.2M | 1.5M |
| Earning Date | 05-01-2026 | 05-06-2026 |
| Dividend Yield | ★ 3.03% | N/A |
| EPS Growth | ★ 238.46 | N/A |
| EPS | ★ 3.56 | 1.30 |
| Revenue | N/A | ★ $2,708,100,000.00 |
| Revenue This Year | $8.01 | $24.55 |
| Revenue Next Year | N/A | $19.18 |
| P/E Ratio | ★ $19.90 | $121.33 |
| Revenue Growth | N/A | ★ 30.73 |
| 52 Week Low | $41.95 | $138.79 |
| 52 Week High | $74.73 | $354.88 |
| Indicator | DINO | PODD |
|---|---|---|
| Relative Strength Index (RSI) | 53.75 | 50.10 |
| Support Level | $66.25 | $141.67 |
| Resistance Level | $73.91 | $161.35 |
| Average True Range (ATR) | 2.17 | 5.56 |
| MACD | 0.09 | 2.03 |
| Stochastic Oscillator | 67.91 | 62.03 |
HF Sinclair is an integrated petroleum refiner that owns and operates seven refineries serving the Rockies, midcontinent, Southwest, and Pacific Northwest, with a total crude oil throughput capacity of 678,000 barrels per day. It can produce 380 million gallons of renewable diesel annually. It holds a marketing business with over 350 distributors and 1,700 wholesale branded sites across 30 states. It also owns and operates 4,500 miles of petroleum product pipelines and terminals principally in the southwestern United States.
Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the US Food and Drug Administration in 2005, approximately 500,000 insulin-dependent diabetic patients are using it worldwide.